Suzhou Zelgen Biopharmaceuticals Co Ltd Cash Flow-to-Debt Ratio
Suzhou Zelgen Biopharmaceuticals Co Ltd cash flow-to-debt ratio. Suzhou Zelgen Biopharmaceuticals Co Ltd (688266) has a Cash Flow-to-Debt Ratio of 0.00x as of September 2025, meaning its operating cash flow of CN¥543.69K could theoretically repay 0% of its total liabilities (CN¥1.86 Billion) in one year. See 688266 financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Suzhou Zelgen Biopharmaceuticals Co Ltd (2016–2024)
Cash flow-to-debt ratio of Suzhou Zelgen Biopharmaceuticals Co Ltd from 2016 to 2024. Historical debt coverage capacity for Suzhou Zelgen Biopharmaceuticals Co Ltd across 9 annual periods. Check 688266 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Suzhou Zelgen Biopharmaceuticals Co Ltd Cash Flow-to-Debt Ratio by Year (2016–2024)
Suzhou Zelgen Biopharmaceuticals Co Ltd cash flow-to-debt ratio by year from 2016 to 2024. Year-by-year debt coverage analysis for Suzhou Zelgen Biopharmaceuticals Co Ltd. For the full cash flow conversion analysis, see cash flow conversion of Suzhou Zelgen Biopharmaceuticals Co Ltd.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.02x | CN¥38.20 Million | CN¥1.75 Billion | ▲ +112.3% |
| 2023 | -0.18x | CN¥-220.31 Million | CN¥1.24 Billion | ▲ +57.8% |
| 2022 | -0.42x | CN¥-370.34 Million | CN¥880.82 Million | ▲ +54.4% |
| 2021 | -0.92x | CN¥-454.62 Million | CN¥492.88 Million | ▲ +25.2% |
| 2020 | -1.23x | CN¥-343.86 Million | CN¥278.69 Million | ▼ -68.6% |
| 2019 | -0.73x | CN¥-180.43 Million | CN¥246.52 Million | ▼ -12.8% |
| 2018 | -0.65x | CN¥-112.44 Million | CN¥173.24 Million | ▲ +55.3% |
| 2017 | -1.45x | CN¥-108.25 Million | CN¥74.61 Million | ▲ +29.0% |
| 2016 | -2.04x | CN¥-56.72 Million | CN¥27.76 Million | — |